The short version of Reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Former Conservative Party minister Penny Mordaunt is to take up a role with British American Tobacco, as part of their Transformation Advisory Board. Having previously ruled out an electoral pact with Reform at a national level, when asked by BBC News if the same applies at a local level in relation to the upcoming council elections, Conservative leader Kemi Badenoch says that local leaders of her party "would be free to share power" with other parties to keep councils running. Asked a similar question later, Nigel Farage, leader of Reform UK, appears to reject the idea although he does say that there could be "working relationships" with other parties. 11 April – Publication of Rishi Sunak's Resignation Honours. They include peerages for Michael Gove, Alister Jack and Simon Hart, and knighthoods for Jeremy Hunt and James Cleverly. Starmer travels to Northern Ireland to meet First Minister Michelle O'Neill and Deputy First Minister Emma Little-Pengelly to discuss US trade tariffs. 12 April – Parliament is recalled to discuss emergency legislation to save the Scunthorpe Steelworks from closure. The legislation will see the UK government take control of the steelworks and preventing owners Jingye from closing it. Liberal Democrat MP Wera Hobhouse speaks of her "shock" after being refused entry to Hong Kong a few days earlier. Rail Minister Lord Peter Hendy refers himself to police after admitting he used a mobile phone while driving a vintage double-decker bus through London.
If complications cannot be controlled or when the liver ceases functioning, liver transplantation is necessary. Survival from liver transplantation has been improving over the 1990s, and the five-year survival rate is now around 80%. The survival rate depends largely on the severity of the disease and other medical risk factors in the recipient. In the United States, the MELD score is used to prioritize patients for transplantation. Transplantation necessitates the use of immune suppressants (ciclosporin or tacrolimus).
== History == In 1968, a reduced T4 half-life in athletes was discovered. This was the first awareness of thyroid hormone concentration alterations that were not a result of thyroid gland or pituitary dysfunction. In 1971, they also found a transient increase in T4 during bicycle training. In 1973, Rothenbuchner et al. discovered that starvation is correlated with reduced T3 concentration. Following this, a similar phenotype was noted in patients with critical illness, tumors, and uremia. The alternative phenotype of type-2 thyroid allostasis was first predicted in 1968, when John W. Mason expected the concentrations of thyroid hormones to rise in situations of psychosocial stress. Mason's postulate was later confirmed by numerous studies.
Sources: en.wikipedia.org
== Structure and enzymatic activity == FAP is a 760 amino acid long type II transmembrane glycoprotein. It contains a very short cytoplasmic N terminal part (6 amino acids), a transmembrane region (amino acids 7–26), and a large extracellular part with an alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. A soluble form of FAP, which lacks the intracellular and transmembrane part, is present in blood plasma. FAP is a non-classical serine protease, which belongs to the S9B prolyl oligopeptidase subfamily. Other members of the S9B subfamily are DPPIV, DPP8 and DPP9. FAP is most closely related to DPPIV (approximately 50% of their amino acids are identical). The active site of FAP is localized in the extracellular part of the protein and contains a catalytic triad composed of Ser624 Asp702 His734 in humans and mice. FAP is catalytically active as a 170kD homodimer and has a dipeptidase and an endopeptidase activity. Several bioactive peptides and structural proteins were reported to be cleaved by FAP, such as neuropeptide Y (NPY), Peptide YY, Substance P (SP), and B-type natriuretic peptide (BNP), human fibroblast growth factor 21 (FGF-21), human alpha2 antiplasmin and denatured collagen I and III. NPY, FGF-21 and alpha2 antiplasmin are considered to be physiological FAP substrates.
== Discovery and structure elucidation == Kedarcidin was first discovered in 1992 when bioassays conducted at Bristol-Myers Squibb indicated the presence of a DNA-damaging chromoprotein in the fermentation broth of an Actinomycete strain. The involvement of a non-peptidic chromophore was deduced by UV spectroscopy, and reverse-phase chromatography was used to separate this noncovalently bound chromophore from its apoprotein host. This isolate—kedarcidin chromophore—decomposed readily under ambient conditions and was shown to possess cytotoxicity (IC50 0.4 ng/ml, HCT-116 human colorectal carcinoma cell line). Subsequent NMR, mass spectrometry, chemical degradation, and derivatization experiments enabled the isolation team to identify the key structural features of kedarcidin chromophore, including the enediyne bicyclic core, the ansa-bridging chloropyridyl ring, the mycarose and kedarosamine sugars, and the naphthoamide appendage. However, due to the challenges posed by the complex structure, the initial report had several errors. The bicyclic core proved particularly difficult to deconvolute, as the interpretation of NOE correlations led the researchers to misassign the relative stereochemistry of the core stereotetrad. Moreover, as global absolute chemistry was assigned on the basis of NOE correlations between the stereodefined L-mycarose sugar and the aglycone, the errors of the stereotetrad propagated to the other two stereocenters of the aglycone. Connectivity of the naphthoamide group to the ansa bridge was also misjudged in the initial report.
Esterification of L-glutamic acid [56-86-0] (1) with ethanol gives Glutamic acid diethyl ester [16450-41-2] (2). Lactam formation occurs on heating to give L-Pyroglutamic acid ethyl ester [7149-65-7] (3). The reduction of the ester with sodium borohydride gives L-Pyroglutaminol [17342-08-4] (4). Treatment with methyl chloride gave (S)-(5-Oxopyrrolidin-2-yl)methyl methanesulfonate [93288-20-1] (5). Displacement of the leaving group with cyanide led to (S)-5-Oxo-2-pyrrolidineacetonitrile [72479-06-2] (6). Catalytic reduction over Rosenmund catalyst in the presence of dimethylamine led to (5S)-5-[2-(dimethylamino)ethyl]pyrrolidin-2-one, PC13306712 (7). Oxidation in the presence of hydrogen peroxide formed the N-oxide (8). Elimination of the amino group in the presence of weak base led to (S)-5-Vinylpyrrolidin-2-one [93288-23-4] (9). Alkylation of the amino group with 2-Chlorobenzyl chloride [611-19-8] (10) in the presence of sodium hydride base led to (5S)-1-[(2-chlorophenyl)methyl]-5-ethenylpyrrolidin-2-one, PC56976994 (11). Treatment of the vinyl group with peroxy acid gave the oxirane. (5S)-1-[(2-chlorophenyl)methyl]-5-(oxiran-2-yl)pyrrolidin-2-one, PC88496451 (12). Treatment with (2R)-N-[(2R)-butan-2-yl]butan-2-amine, PC6347588 (13) completed the synthesis of Z4349 (14).
Sources: en.wikipedia.org
== Production == The method of freeze-drying is used for production. The liquid of the bean curd turns into ice. Freezing changes the color, texture, size, and weight, after which it is thawed. At the end of the process, a beige and sponge-like tofu essence are achieved.
Furthermore, although flower development is induced at warmer temperatures (20–25 °C or 68–77 °F), elongation of the flower stalk and proper flowering is dependent on an extended period of low temperature (< 10 °C or 50 °F). Tulip bulbs imported to warm-winter areas are often planted in autumn to be treated as annuals. The colour of tulip flowers also varies with growing conditions.
== AFL career == Pears was drafted by Essendon with pick 23 in the 2007 national draft and debuted in 2008. He played the role of a key position defender in his second season, taking on big dominant forwards such as Daniel Bradshaw, Jarryd Roughead and Justin Koschitzke. After playing on Brendan Fevola in round 13, 2009, he was the round nominee for the Rising Star. Off-season surgery on a foot fracture that set back his return to senior football saw Pears’ bad run with injury continue in 2011. He played his first game of the year against North Melbourne in round 13, but saw his season further stifled with injury after breaking his lower leg and then straining his hamstring in the elimination final. Injury continued to force him to sit on the sidelines in the years after, managing 23 games in the next four seasons. Then on 12 January 2016 Pears was named as one of 34 past and present Essendon players found guilty over their use of illegal supplements during the 2012 AFL season. As a result, Pears was suspended for two years, which, as a result of backdating, saw him suspended between January and November 2016, which meant he missed the entire 2016 AFL season. He did not return to the AFL after his suspension, announcing his retirement from the league on 8 September 2016 to pursue a career in firefighting.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.